<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4240">
  <stage>Registered</stage>
  <submitdate>29/10/2013</submitdate>
  <approvaldate>29/10/2013</approvaldate>
  <nctid>NCT01976299</nctid>
  <trial_identification>
    <studytitle>AVERT Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN</studytitle>
    <scientifictitle>AVERT Clinical Trial</scientifictitle>
    <utrn />
    <trialacronym>AVERTâ„¢</trialacronym>
    <secondaryid>TP-6364</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Contrast Induced Nephropathy (CIN)</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - AVERT

Experimental: Active Treatment - Standard of Care with the AVERT system

No Intervention: Standard of Care - 


Treatment: devices: AVERT


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Effectiveness Endpoint - Reduction in the incidence of Contrast Induced Nephropathy (CIN) by evaluating Serum Creatinine levels in subjects for up to 5 days.</outcome>
      <timepoint>3-5 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint- Number of Participants Experiencing a Device Related Serious Adverse Event - Analyze the incidence of device related serious adverse events within the treatment arm.</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Endpoint 1- - Comparison in contrast media volume required between active treament and standard of care.</outcome>
      <timepoint>30 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Endpoint 2- Comparison of Serious Adverse Events. - Comparing event rates of serious adverse events 30 days following the index procedure.</outcome>
      <timepoint>30 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Endpoint 3- Change in Kidney Function. - Change in kidney function by analyzing eGFR 3 to 5 days post procedure.</outcome>
      <timepoint>3-5 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The subject is a candidate for a therapeutic percutaneous coronary intervention (PCI)
             procedure.

          -  The subject has documented chronic kidney disease (CKD)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject is in acute renal failure

          -  Assessment of ventricular function that cannot be accomplished without the use of the
             CM.

          -  Subject has acute STEMI within 72 hours prior to planned PCI procedure, or is
             currently having an acute STEMI.

          -  Subject is unable to undergo peri-procedural hydration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>578</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Heart Center Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Osprey Medical, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the
      kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced
      nephropathy (CIN).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01976299</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Roxana Mehran, MD, FACC</name>
      <address>Icahn School of Medicine at Mount Sinai</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>